Teva Pharma’s most recent trend suggests a bullish bias. One trading opportunity on Teva Pharma is a Bull Put Spread using a strike $35.00 short put and a strike $30.00 long put offers a potential -0.4% return on risk over the next 8 calendar days. Maximum profit would be generated if the Bull Put Spread were to expire worthless, which would occur if the stock were above $35.00 by expiration. The full premium credit of $-0.02 would be kept by the premium seller. The risk of $5.02 would be incurred if the stock dropped below the $30.00 long put strike price.
The 5-day moving average is moving up which suggests that the short-term momentum for Teva Pharma is bullish and the probability of a rise in share price is higher if the stock starts trending.
The 20-day moving average is moving up which suggests that the medium-term momentum for Teva Pharma is bullish.
The RSI indicator is below 20 which suggests that the stock is in oversold territory.
To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here
LATEST NEWS for Teva Pharma
Is Teva’s Situation Really So Dire?
Fri, 08 Nov 2013 17:55:57 GMT
Motley Fool – Despite Teva’s poor performance recently, it still has several strong points that could revive its stock. How is Teva measuring up to Pfizer and Impax Laboratories?
Teva, Asthma and Allergy Foundation of America announce survey findings
Fri, 08 Nov 2013 13:05:40 GMT
theflyonthewall.com – Teva, Asthma and Allergy Foundation of America announce survey findings
Survey Data Reinforces Patient Benefit of Asthma Rescue Inhalers with Integrated Dose Counters
Fri, 08 Nov 2013 13:00:00 GMT
Business Wire – Teva Pharmaceuticals Industries Ltd. and the Asthma and Allergy Foundation of America announced today findings from a recent patient survey on quick-relief metered dose inhaler design.
OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Third Quarter 2013 and Addresses Key Questions from Investors on Quarterly Conference Call
Thu, 07 Nov 2013 21:00:00 GMT
PR Newswire – BOTHELL, Wash. and VANCOUVER, British Columbia, Nov. 7, 2013 /PRNewswire/ — OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) today announced third quarter 2013 financial results and will address frequently …
Pharmaceutical Stocks: Solid Dividends, Great Growth Potential
Thu, 07 Nov 2013 12:20:17 GMT
Motley Fool – Do Teva, Eli Lilly, Bristol-Myers Squibb, or AbbVie belong in your portfolio?
Also on Market Tamer…
Follow Us on Facebook